Table 3.
Baseline demographic and clinical features of RA and OA patients in the study of PGC-1β expression in FLS by qPCR and western blot
| Characteristic | RA patients (n = 8) | OA patients (n = 6) |
|---|---|---|
| Demographic | ||
| Age, yrs, median (range) | 55 (33 to 70) | 57 (51 to 68) |
| Female, n (%) | 8 (100) | 6 (100) |
| Disease status | ||
| Disease duration, mo, median (range) | 78 (2 to 240) | 36 (12 to 168) |
| ESR, mm/h, median (range) | 50 (11 to 83) | 18 (12 to 32) |
| CRP, mg/dl, median (range) | 1.53 (0.02 to 4.55) | 0.33 (0.08 to 1.11) |
| Rheumatoid factor-positive, n (%) | 7 (87.5) | NA |
| Anti-CCP-positive, n (%) | 8 (100) | NA |
| DAS28, median (range) | 4.36 (3.06 to 5.82) | NA |
| Previous medications, n (%) | NA | |
| Corticosteroids | 3 (37.5) | NA |
| Methotrexate | 4 (50) | NA |
| Leflunomide | 3 (37.5) | NA |
| Hydroxychloroquine | 2 (25) | NA |
| Infliximab | 1 (12.5) | NA |
| Etanercept | 1 (12.5) | NA |
FLS, fibrolast-like synoviocytes; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, disease activity score 28-joint assessment; n, number of patients; RA, rheumatoid arthritis; OA, osteoarthritis; NA, not applicable.